In the study of Mautner et al. [5], 21% of the patients with molecularly ascertained type-1 NF1 deletions had an MPNST, thereby confirming the increased risk with respect to this malignant tumor experienced by patients with type-1 NF1 deletions. Here, NF1 is linked to cancer.